CN209075645U - Blood toxicity absorber - Google Patents
Blood toxicity absorber Download PDFInfo
- Publication number
- CN209075645U CN209075645U CN201820017994.1U CN201820017994U CN209075645U CN 209075645 U CN209075645 U CN 209075645U CN 201820017994 U CN201820017994 U CN 201820017994U CN 209075645 U CN209075645 U CN 209075645U
- Authority
- CN
- China
- Prior art keywords
- blood
- sealant
- hollow
- opening
- absorber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006096 absorbing agent Substances 0.000 title claims abstract description 27
- 230000007681 cardiovascular toxicity Effects 0.000 title claims abstract description 27
- 210000004369 blood Anatomy 0.000 claims abstract description 62
- 239000008280 blood Substances 0.000 claims abstract description 62
- 210000002381 plasma Anatomy 0.000 claims abstract description 38
- 239000000565 sealant Substances 0.000 claims abstract description 34
- 238000001179 sorption measurement Methods 0.000 claims abstract description 34
- 239000003463 adsorbent Substances 0.000 claims abstract description 30
- 239000012510 hollow fiber Substances 0.000 claims abstract description 27
- 238000000926 separation method Methods 0.000 claims description 10
- 239000003053 toxin Substances 0.000 claims description 7
- 231100000765 toxin Toxicity 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 230000017531 blood circulation Effects 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000002969 morbid Effects 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000005457 optimization Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 239000000470 constituent Substances 0.000 description 11
- 239000000306 component Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012503 blood component Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Abstract
This case is related to blood toxicity absorber, comprising: adsorption column, inner hollow, both ends are respectively provided with the first opening and the second opening；First and second opening is respectively equipped with the first and second sealant；One end of hollow-fiber film is through to the first sealant, and the other end is through to the second sealant；The first opening of first end cover connection, has a blood entry port；The second opening of second end cover connection, has blood outlet；Wherein, first inner chamber is formed between the first end cover and first sealant；Second inner chamber is formed between the second end cover and second sealant；Adsorbent is filled with inside the adsorption column；The blood plasma filter mouth with strainer is additionally provided on the outside of second sealant edge between the adsorption column；The utility model shortens Blood index process significantly by optimization adsorber structure, and absorption is accurate, Small side effects；The advantages of the utility model has consumptive material reduction compared with the existing technology, and therapeutic equipment simplifies, and operation difficulty reduces.
Description
Technical field
The utility model relates to a kind of apparatus for purifying blood, especially it is a kind of carry out simultaneously blood constituent separation with it is endogenous
Property/heterotoxin remove blood toxicity absorber.
Background technique
Plasma sorption therapy is small to injury of blood cell, small on the influence of inside of human body environment, answers extensively in field of blood purification
With.The basic principle of plasma sorption therapy is to guide to patient's body blood in vitro, by the way that first haemocyte is separated with blood plasma, then
Specific aim, which adsorbs the morbid substance in blood plasma, to be removed, and the purpose for the treatment of disease is had reached.According to the difference of selected adsorbent,
The therapeutic modality is for human autoimmune diseases, metabolic disease, endogenous/heterotoxin poisoning etc..
Fig. 1 is the flow chart of plasma sorption therapy common at present, as shown, the blood of human body artery outflow is along arrow
Shown direction first enters in plasma separator B through blood pump A, by the sieving actoion of plasma separator, by blood plasma and haemocyte
It separates, is then re-introduced into the blood plasma separated in plasma adsorption column D by blood pump C, it is built-in using plasma adsorption column
The suction-operated specific aim of the adsorbent of load removes the various pathogenic or noxious materials in blood plasma, this plasma sorption therapy method
It is not only at high price, but also there is, side effect big disadvantage excessive beneficial to component damages.
Current plasma sorption therapy price is very high, and one of reason is exactly that a full set of plasma adsorption equipment cost occupies height not
Under, concatenated equipment is more during plasma sorption therapy, and pipeline is long, and complicated for operation, the indication for needing to control is more, this is resulted in
The blood volume of extracorporal circulatory system is larger, and the medical instrument of contact is more, this also makes molten while the body burden for increasing patient
The probability that the problems such as blood, blood coagulation occurs increases, and increases security risk when treatment, these problems lead to plasma sorption therapy mould
Formula is difficult to be widely popularized at home.
Summary of the invention
The technical problem to be solved by the present invention is to provide a kind of blood toxicity absorber, make blood constituent separation with it is interior
Source property/heterotoxin removing can carry out simultaneously, and be dedicated to reducing equipment used in plasma sorption therapy and pipeline consumption
Material, reduces the blood flow of extracorporal circulatory system, realizes accurate absorption, reduces the loss of human body beneficial ingredient, such as albumin, avoids pair
Human body causes excessive side effect, simplifies structure simultaneously, and cost reduces.
In view of the above shortcomings of the prior art, the utility model provides a kind of blood toxicity absorber, comprising:
Adsorption column, inner hollow, both ends are respectively provided with the first opening and the second opening；First opening is equipped with first
Sealant, second opening are equipped with the second sealant；
Hollow-fiber film, one end are through to the first sealant, and the other end is through to the second sealant；
First end cover connects first opening, has a blood entry port；
Second end cover connects second opening, has blood outlet；
Wherein, first inner chamber is formed between the first end cover and first sealant；The second end cover and institute
It states and is formed with second inner chamber between the second sealant；
The adsorbent and water for injection being in contact with hollow-fiber film outer wall are also filled with inside the adsorption column；
Blood plasma filter mouth is additionally provided on the outside of second sealant edge between the adsorption column, blood plasma filter mouth has
Strainer.
Preferably, the blood toxicity absorber, wherein the surface area of the hollow-fiber film is 0.3-2.6m2。
Preferably, the blood toxicity absorber, wherein the internal diameter of the hollow-fiber film is 0.1mm-5mm, wall
The average pore size in hole is 6nm-500nm.
Preferably, the blood toxicity absorber, wherein the adsorbent is that specific surface area is 1-2000 m2It is/g, outer
The spherical adsorbent that diameter is 0.1-2.0mm, aperture is 0.1nm-100nm.
The adsorbent can be directed to different morbid substances, select the immobilized ball for having corresponding aglucon, respective aperture, respective strengths
Shape adsorbent, to adapt to the treatment of various disease, it should be noted that should be taken into account spherical absorption when loading spherical adsorbent
The physical strength of agent avoids loading the micromorphology that pressure crosses the spherical adsorbent of havoc, influences adsorption effect.
The selection of the hollow-fiber film and spherical adsorbent and its amount ratio, can be according to different purposes, using now
There is the method for determining the amount of the quantity and adsorbent in plasma adsorption column of hollow fibre in plasma separator in technology to be calculated.
Preferably, the blood toxicity absorber, wherein first sealant and the second sealant are polyurethane adhesive
Adhensive layer.
The filter opening aperture of the strainer is less than the partial size of adsorbent.
The blood entry port and blood outlet are the general standard interface of extracorporeal circulation pipeline.
The hollow-fiber film includes one or more normal plasma seperation films.
Endogenous with above structure/heterotoxin absorber, for blood constituent separation hollow-fiber film and
The spherical adsorbent envelope for carrying out the absorption of blood constituent toxin fills and is filled in a cylinder intracavity, blood by blood inlet into
Enter hollow fiber membrane inner cavity, under the action of transmembrane pressure, the plasma composition in blood passes through the micropore on hollow-fiber film side wall
It filters out, enters spherical adsorbent filled cavity；In adsorbent filled cavity, blood constituent and the spherical adsorbent separated
Surface comes into full contact with, and the toxin for needing to remove in blood constituent is adsorbed by adsorbent；In this process, blood constituent separation and
Toxin absorption is carried out continuously
The utility model has the advantages that
The utility model makes blood constituent separation and blood toxicity adsorb while carry out by optimization adsorber structure, makes
Blood separation and adsorption process significantly shorten, and reduce the blood volume of extracorporal circulatory system, absorption is accurate, and Small side effects reduce patient
Burden and blood incompatibility risk；Meanwhile the utility model can reduce the pipeline consumptive material of plasma sorption therapy, simplify
Required equipment reduces operation difficulty and allows plasma sorption therapy to exist so that the material cost of plasma sorption therapy substantially reduces
It is domestic easier universal, benefit many patients.
Detailed description of the invention
Fig. 1 is the flow chart of the plasma sorption therapy of current main-stream.
Fig. 2 is the cross-sectional view of the utility model blood toxicity absorber.
Fig. 3 is the three-dimensional view of the utility model blood toxicity absorber.
Fig. 4 is the schematic diagram of internal structure of the utility model blood toxicity absorber.
Fig. 5 is the blood outflow end schematic perspective view using the utility model blood toxicity absorber.
Fig. 6 is the flow chart using the utility model blood toxicity absorber.
Specific embodiment
The utility model is further described in the following with reference to the drawings and specific embodiments.
Embodiment 1
The utility model is described in further detail below by embodiment, to enable those skilled in the art's reference say
Bright book text can be implemented accordingly.
Such as " have " it should be appreciated that used herein, "comprising" and " comprising " term are not precluded one or more
The presence or addition of a other elements or combinations thereof.
Embodiment 1
As shown in Fig. 2,3,4,5, a kind of blood toxicity absorber, comprising:
Adsorption column 2, inner hollow, both ends are respectively provided with the first opening 203 and the second opening 204；First opening
203 are equipped with the first sealant 103, and second opening 204 is equipped with the second sealant 301；
Hollow-fiber film 201, one end are through to the first sealant 103, and the other end is through to the second sealant 301；
First end cover 1 connects first opening 203, has a blood entry port 101；
Second end cover 3 connects second opening 204, has blood outlet 303；
Wherein, first inner chamber 102 is formed between the first end cover 1 and first sealant 103；The second end
Second inner chamber 302 is formed between lid 3 and second sealant 301；
The adsorbent 202 being in contact with 201 outer wall of hollow-fiber film and injection are also filled with inside the adsorption column 2
Water；
Blood plasma filter mouth 304, the blood plasma are additionally provided on the outside of second sealant, 301 edge between the adsorption column 1
Filtering mouth has strainer 305.
In this embodiment, the first and second sealant layer uses polyurethane material；The internal diameter of adsorption column 2 is about
65mm, it is 500 μm that hollow-fiber film 201, which selects outer diameter, the plasma separation membrane that internal diameter is 300 μm, and quantity is 4600, and length is about
For 200mm；Adsorbent is in spherical particle, is to adsorb resin by the macropore neutrality of carrier of polystyrene-divinylbenzene, dosage is
180ml。
This embodiment blood component adsorption device in the fabrication process, can be first by hollow-fiber film 201, referring to existing skill
The production method of hollow fibre molecular filter in art is poured by PU sealant and tunica fibrosa is fixed in cylinder 2.By cutting glue
The first and second sealant layer is formed after processing, is then packed into from the reserved channel in 301 periphery of the second sealant layer by pre-
The polystyrene-divinylbenzene macropore neutrality of processing adsorbs resin.
Embodiment 2
This embodiment and 1 structure of example are essentially identical, the difference is that:
In this embodiment, the internal diameter of adsorption column 2 is about 70mm, and it is 350 μm that hollow-fiber film, which selects outer diameter, and internal diameter is
200 μm of plasma separation membrane, quantity are 6000, and length is about 150mm；Adsorbent is spherical immunosorbent, and dosage is
150ml。
Embodiment 3
Such as Fig. 6, when in use, the blood drawn from patient's body is along arrow side for the blood toxicity absorber of the utility model
To flowing, blood pump A is first passed through, then enters first inner chamber from the blood inlet of the first end cover 1 of blood toxicity absorber D '
102, subsequently into hollow-fiber film 201, the plasma composition in blood passes through the membranous wall of hollow-fiber film 201, divides from blood
It separates out and, the gap between hollow-fiber film 201, blood separated component is in contact with adsorbent 202 at this time, cause therein
Disease substance or toxin are adsorbed the absorption of agent 202 and remove, and blood separated component is purified；Blood after the absorption of adsorbent 202
Separated component comes out from blood plasma filter mouth 304 and flows into second inner chamber 302, with the blood that is flowed out from hollow fibre pipe 201 it is main at
Divide and converge, becomes the blood by purification, then purified blood flows out from blood outflow port, again defeated the Huis' body；?
During this, blood constituent separation and toxin absorption are carried out continuously.
Take this, it can be seen that the blood toxicity absorber of the utility model can be such that blood component adsorption process shortens, and reduce
The blood flow of extracorporal circulatory system is to reduce the burden of patient and the risk that blood is incompatible；In addition, the blood of the utility model
Not only structure is simple for liquid ingredient tank, and component is few, and easy to operate, low for equipment requirements, only requires blood cleaning equipment
There is a blood pump A to be sufficient (see Fig. 6)；Furthermore, it is possible to select respective fiber membranous wall according to the toxin to be removed of blood constituent
The blood constituent separating membrane of hole size accomplishes physics specific selection, reduces the loss of human body beneficial ingredient, avoids existing side
The loss of beneficiating ingredient existing for method is excessive, the big disadvantage of side effect.
It is not only in the description and the implementation although the embodiments of the present invention have been disclosed as above
Listed utilization, it can be applied to various fields suitable for the present invention completely, for those skilled in the art,
Other modifications may be easily implemented, therefore without departing from the general concept defined in the claims and the equivalent scope, this reality
It is not limited to specific details and embodiment shown and described herein with novel.
Claims (7)
1. a kind of blood toxicity absorber characterized by comprising
Adsorption column, inner hollow, both ends are respectively provided with the first opening and the second opening；First opening is equipped with the first sealing
Layer, second opening are equipped with the second sealant；
Hollow-fiber film, one end are through to the first sealant, and the other end is through to the second sealant；
First end cover connects first opening, has a blood entry port；
Second end cover connects second opening, has blood outlet；
Wherein, first inner chamber is formed between the first end cover and first sealant；The second end cover and described the
Second inner chamber is formed between two sealants；
The adsorbent and water being in contact with hollow-fiber film outer wall are also filled with inside the adsorption column；
Blood plasma filter mouth is additionally provided on the outside of second sealant edge between the adsorption column, which, which filters mouth, has filter
Net；
Blood enters first inner chamber from the blood inlet of the first end cover, the blood subsequently into hollow-fiber film, in blood
Slurry ingredient passes through the membranous wall of hollow-fiber film and separates from blood, the gap between the hollow-fiber film；This
When blood separated component be in contact with adsorbent, morbid substance or toxin therein are adsorbed by adsorbent removing；It is inhaled through adsorbent
Attached blood separated component flows into second inner chamber from blood plasma filter mouth, the blood with hollow-fiber film outflow out
Liquid principal component is converged, and the blood by purification is become, and then purified blood flows out from blood outflow port.
2. blood toxicity absorber as described in claim 1, which is characterized in that the surface area of the hollow-fiber film is 0.3-
2.6m2。
3. blood toxicity absorber as described in claim 1, which is characterized in that the internal diameter of the hollow-fiber film is 0.1mm-
5mm, the average pore size of cinclides are 6nm-500nm.
4. blood toxicity absorber as described in claim 1, which is characterized in that the adsorbent is that specific surface area is 1-
2000m2The spherical adsorbent that/g, outer diameter 0.1-2.0mm, aperture are 0.1nm-100nm.
5. blood toxicity absorber as described in claim 1, which is characterized in that the filter opening aperture of the strainer is less than adsorbent
Partial size.
6. blood toxicity absorber as described in claim 1, which is characterized in that the hollow-fiber film is plasma separation membrane.
7. blood toxicity absorber as described in claim 1, which is characterized in that first sealant and the second sealant are
Adhesive for polyurethane layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820017994.1U CN209075645U (en) | 2018-01-05 | 2018-01-05 | Blood toxicity absorber |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820017994.1U CN209075645U (en) | 2018-01-05 | 2018-01-05 | Blood toxicity absorber |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN209075645U true CN209075645U (en) | 2019-07-09 |
Family
ID=67112072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201820017994.1U Active CN209075645U (en) | 2018-01-05 | 2018-01-05 | Blood toxicity absorber |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN209075645U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108175888A (en) * | 2018-01-05 | 2018-06-19 | 苏州仝康医疗科技有限公司 | Blood toxicity absorber |
-
2018
- 2018-01-05 CN CN201820017994.1U patent/CN209075645U/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108175888A (en) * | 2018-01-05 | 2018-06-19 | 苏州仝康医疗科技有限公司 | Blood toxicity absorber |
| CN108175888B (en) * | 2018-01-05 | 2024-06-07 | 苏州仝康医疗科技有限公司 | Blood toxin adsorber |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8771513B2 (en) | Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof | |
| CN102631722B (en) | Blood plasma separation adsorber capable of blood purification | |
| CN204275132U (en) | A kind of apparatus for purifying blood that synchronously can realize dialysing and perfusion is treated | |
| WO2016060209A1 (en) | Body fluid filtration device of hollow fiber membrane type, and method for filtrating protein solution | |
| CN105343954B (en) | Compound apparatus for purifying blood and preparation method thereof | |
| CN203507201U (en) | Separating type hemodialysis absorber | |
| CN209075645U (en) | Blood toxicity absorber | |
| CN108175888A (en) | Blood toxicity absorber | |
| CN205073372U (en) | Compound blood purifying device | |
| CN203139198U (en) | Simple blood purifier | |
| CN108404239A (en) | Integral type blood plasma detaches myoglobins absorber | |
| CN105214158B (en) | Apparatus for purifying blood and blood purification system | |
| JP7255899B2 (en) | Devices for selective removal of molecules from tissue or fluids | |
| CN212662357U (en) | A portable blood purification device | |
| CN101601970B (en) | Filter and pipeline system used for cerebrospinal fluid purification device | |
| CN203507204U (en) | Integrated hemodialysis absorber | |
| CN108434542A (en) | Integral type blood plasma detaches blood perfusion device | |
| JP2006160731A (en) | Blood ingredient-recovering apparatus | |
| CN203943948U (en) | A kind of blood perfusion device sorbent assemblies | |
| CN105214157B (en) | Apparatus for purifying blood and system | |
| CN218165728U (en) | Perfusion dialysis auto-change over device | |
| CN108465136A (en) | Integral type blood plasma detaches Endotoxin adsorption device | |
| CN108653846A (en) | Integral type blood plasma protein isolate A immuno absorbence devices | |
| HK40043641A (en) | Device for the selective removal of molecules from tissues or fluids | |
| HK40043641B (en) | Device for the selective removal of molecules from tissues or fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |